Penn’s one-stop solution for technology commercialization and entrepreneurship
I’m a Faculty Member or Researcher
I’m with a Company
I’m an Entrepreneur
I want to:
Translating Discoveries
PCI helps to translate discoveries and ideas created at the University of Pennsylvania into new products and businesses for societal benefit.
We actively facilitate a broad range of technology development connections between Penn and the private sector. Whether the end result is a technology license, an R&D alliance, or the formation of a new venture, PCI serves as a dedicated one-stop shop for commercial partnering with Penn.
Access the FY2025 Year in Review
#1
in licensing revenue 5th year in a row
26
Startups launched
>$591M
in investment capital raised or received by Penn affiliated startups
99
New patents awarded
Penn Launches StartUP Fund
Penn has announced the launch of its StartUP Fund, a new early-stage investment fund dedicated to supporting startup companies founded by Penn researchers and based on innovations created at the University.
Managed by Penn’s Office of the Chief Investment Officer (OCINO), and backed by a $10M commitment from the University, the StartUP Fund provides vital seed-stage capital investments to qualifying startups drawn from across the Penn research community.
Funds invested into Penn startup companies will help to further advance Penn’s research breakthroughs, and any returns that the fund realizes will be reinvested back into the fund.
Learn more and access the application here.
Penn Startups Raising Money
Discover the Penn startup companies raising capital in 2026. Companies listed in red text are clickable and linked to their website. Read the list here.
Watch a Recording of our Innovation @ Penn Panel
PCI hosted our Innovation @ Penn program in San Francisco on January 12, 2026. This signature event, held concurrently during the annual JP Morgan Healthcare Conference, featured a panel with leading luminaries:
- Peter Marks, MD, PhD, Senior Vice President of Molecule Discovery & Head of Infectious Disease at Eli Lilly, and former Director of the FDA’s Center for Biologics Evaluation and Research
- Jim Wilson, MD, PhD, Emeritus Professor of Medicine (Translation of Medicine and Human Genetics) at Penn Medicine, Founder and CEO of Gemma Biotherapeutics, and Founder and Executive Chair of Franklin Biolabs
- Allison Rae Greenplate, PhD, Adjunct Assistant Professor of Systems Pharmacology and Translational Therapeutics and Director of Immune Health at Penn Medicine
- Laura Shawver, PhD, former President and CEO of Capstan Therapeutics, who served as moderator of the panel
- Jonathan Epstein, MD, PhD, Dean, Perelman School of Medicine and Executive Vice President of the University of Pennsylvania for the Health System, who delivered keynote remarks
Read the Latest News from PCI on LinkedIn
PCI’s New Technology LinkedIn Page
PCI recently launched a new LinkedIn page showcasing our technologies that are currently available for investment and partnership opportunities. Follow here.
Available Technologies
Find technology opportunities by sector or search:
Nanotechnology | Antibody | Optics & Photonics | Medical Devices | COVID-19 | Immunology | Oncology | Materials | Bioengineering | Neurodegenerative Diseases
View all technologies
Recent News
All NewsCapstan Therapeutics Acquired by AbbVie for $2.1B
Penn Medicine’s Kiran Musunuru Featured in The New York Times for Gene Therapy Breakthrough
Penn Engineering’s Liang Feng Conducts Promising Research on Nonlinear Neural Networks to Train AI on Lightspeed
New Tools for Treating Advanced Retinal Degenerations Developed by Penn Vet Researchers
Discover CAR T-cell technology at Penn
Our latest CAR T-cell enhancement portfolio features innovations poised to transform treatment efficacy with boosted cytokine activity/metabolism, streamlined manufacturing, and reduced T-cell exhaustion. Join us in turning lab discoveries into real-world impact through licensing opportunities with PCI.
Upcoming Events
All Events